首页 联系我们
 
 
中文版
 
English
首页 学会简介 学会章程 组织机构 专业委员会 科技奖励 学术活动 会议注册 毒理学资格认证 继续教育 毒理学通讯 ToxRes 杂志 科普与科技信息 地方学会 党建工作
 
中国毒理学会专业委员会换届改选表格
  当前浏览位置:首页 >> 学术活动
 
2017年国际免疫毒理与安全评价培训班(第二轮通知)
【 日期:2017-9-14    发布:中国毒理学会 】

  “2017年国际免疫毒理与安全评价培训班”将于2017年10月11-13日在上海举办。培训班由美国毒理学院(American College of Toxicology ,ACT)和中国毒理学会联合主办,国家上海新药安全评价研究中心和中国药理学会药物毒理专业委员会共同承办。
  美国毒理学院(ACT)是一个国际上享有良好声誉,以继续教育和专业培训著称的非盈利学术团体,ACT的培训老师和工作人员均为志愿者,通过共享自己的专业知识和丰富经验提供国际一流的继续教育培训。此次培训班所有演讲嘉宾均来自ACT。
  中国毒理学会是中国科学技术协会所属国家一级学会、是国内毒理学科技界的最高学术团体。学会以服务于广大毒理学科技工作者,促进毒理学科学技术的繁荣和发展,促进中国毒理学科技人才的成长和提高为宗旨。学会目前有26个专业委员会、13000余名注册会员,152个团体会员单位。
  此次培训班将针对药物的免疫毒性评价方法和临床前评价热点问题,邀请在相关领域有丰富实践经验的国内外知名专家学者,对免疫毒性评价的国内外现状、问题、试验设计和方法以及国内外相关指导原则进行详细的讲解,对研究者和评价者有重要参考价值。除了讲解和回答问题外,会议还将专门安排案例分析与讨论,由国内外专家讲述介绍实例、解答参会人员实践中碰到的问题,讨论提出实际解决方案,以便参与者不仅能很好的消化和掌握培训内容,而且解决实际工作中的一些疑难。
  会议期间还将举办实验动物设施设备、科研仪器设备、软件以及其他科技产品等科技展览,在参会的同时了解这些行业的前沿与发展。同时,主办和承办单位欢迎生物和医药科技企业、厂家等参展,加深对客/用户的了解和交流。
  本次培训的语言为英语或中文,培训幻灯为中、英文,会议现场拟配备同声传译,讨论阶段有专业人员协助翻译。我们诚挚地邀请从事药物非临床评价的研究人员及相关管理人员、产品研发企业的项目管理和研究人员共赴上海参加此次难得的国际一流继续教育和研修培训和盛会。

一、时间及地点:
时间: 2017年10月11日至10月13日,会期2天半
地点:上海淳大万丽酒店(准五星)
上海市迎春路719号 (见附件3:交通指南)
二、会议日程安排
2017年10月10日下午: 注册报到
2017年10月11日全天: 培训报告
2017年10月12日全天: 培训报告
2017年10月13日上午: 培训报告
详细的会议议程见附件1。

三、会议报名
1、会议回执报名:请填写报名回执并发邮件或传真至会务组(会务组联系方式见后):
2、链接和二维码报名:通过报名链接http://meeting.ai-shu.com/Participants/Register报名或扫描二维码报名。
参会报名截止到2017年09月30日。


 

序号 参会类型 网上缴费
(8月30日前)
现场缴费
1 会员 2400元 2600元
2 非会员 2600元 2800元
备注:会员指主办方、承办方学会会员,需提供会员证原件或复印件。

会议注册费包括会务费、资料费、讲课费、培训证书、会议期间餐饮(11号-12号晚餐、11号-13日午餐)等费用。由中国毒理学会统一开具增值税普通发票
缴费方式(网上转账和支付宝转账请务必备注姓名和单位):
1、网上转账:
开户名:中国毒理学会
开户银行:中国工商银行北京市分行永定路支行
帐号:0200004909014450531
2、报到时缴纳注册费(现金/支付宝)


四、酒店预订

序号 酒店名称 单间 标间
1 淳大万丽酒店 1000元(含单早) 1000元(含双早)
2 宜必思酒店 400元(含单早) 400元(含双早)

凡在2017年09月15日前注册并缴纳注册费者,可以保证在会场酒店的住宿预订安排;09月15日之后交费注册的概不保证。

五、如需咨询会议相关信息,可联系:
联系人1:
刘丹丹(国家上海新药安全评价研究中心)
联系电话:021-60211990
传真: 021-50801259
电子邮箱:ddliu@ncdser.com
联系人2:
陈丽(国家上海新药安全评价研究中心)
联系电话:021-60211999-3106
传真: 021-50801259
电子邮箱:lchen@ncdser.com
联系人3:
李娜(国家上海新药安全评价研究中心)
联系电话:021-60211999-3135
传真: 021-50801259
电子邮箱:nli-2@ncdser.com

主办方:
American College of Toxicology (ACT)
中国毒理学会

承办方:
国家上海新药安全评价研究中心
中国药理学会药物毒理专业委员会

 

嘉宾介绍:

Florence G. Burleson, MSM, Ph.D, has worked at the National Institute of Environmental Health Sciences as a guest researcher, at Procter and Gamble as a contractor for Advanced Tissue Sciences, Inc., and is presently at Burleson Research Technologies, Inc. (BRT). Dr. Burleson is co-founder of BRT where she currently serves as Executive VP and Senior Director of Nonclinical Studies.Dr. Burleson is a member of ACT and SOT. She was elected to the ACT Outreach committee in 2013 and ACT Council in 2016. Dr. Burleson served as ACT representative and as Incoming Chair, Chair, and Past Chair of the Scientific Liaison Coalition (SLC), a coalition of societies to increase the impact of the science of toxicology to improve public health. She is also a member of Editorial Board of the International Journal of Toxicology.
Gary R. Burleson, Ph.D, his background includes clinical experience at Milwaukee County General Hospital, government regulatory experience at the USEPA, and pharmaceutical experience in drug discovery at Procter & Gamble.  He cofounded Burleson Research Technologies, Inc. (BRT) in 1996. He is currently President and CEO of BRT, and is an Adjunct Professor at North Carolina State University.  He is Senior Editor of Methods in Immunotoxicology, Volumes 1 and 2; a member of the editorial board of the Journal of Immunotoxicology; Science Review Board, US EPA; and is past president of the Immunotoxicology Discussion Group (IDG).  He has served as Chairman, Membership Committee and President of the Immunotoxicology Specialty Section, SOT; Conference Chair, Immunotoxicology V Meeting; Organizer, Continuing Education Course entitled “Immunotoxicology,” for 19th Annual Society of Toxicologic Pathology Meeting. 
Hanan Ghantous, Ph.D, DABT, joined the US Food and Drug Administration as a pharmacology/toxicology reviewer in 2001, and since 2007 she has been the Pharmacology/Toxicology supervisor at the Division of Antiviral Products, Center for Drug Evaluation and Research. Dr. Ghantous has presented at national and international scientific and regulatory meetings, has served on several US FDA committees, has been involved in writing Guidance documents and has represented the Agency at various public forums. Dr. Ghantous has been a member of the Society of Toxicology since 1989 and the American College of Toxicology since 2000. She served on the Continuing Education Committee of the Society of Toxicology (2010–2013). Dr. Ghantous is one of the founders of the Biotechnology Specialty Section and served as a VP- elect, VP, President and past president of the specialty section (2010-2013). She also served as a member of the Board of Directors of the American Board of Toxicology (2010–2014) and was the president of the board for 2013-2014. She also served on council of the American College of Toxicology (2011-2013) and as VP- elect, VP, President and past president for the American College of Toxicology (2014-2017).
Hervé N. Lebrec, Ph.D, DABT, received a doctorate in Pharmacy and a PhD degree in Toxicology from the University Paris XI in 1992 and continued his training as a postdoctoral fellow at the USEPA in Research Triangle Park in 1992 and 1993. He then occupied Faculty positions at the School of Pharmacy Paris XI until 1999. Dr Lebrec’s career in the pharmaceutical industry began in 2000 at 3M Pharmaceuticals. In 2006, he joined the toxicology department at Amgen, where he currently is a Scientific Director at the South San Francisco site in California and works as a Lead for both small molecule-, biologics- and cellular therapy-based projects. He currently co-chairs the immunotoxicology technical committee (ITC) of HESI.
Huaizhong Hu, Ph.D, DABT, serves currently as the vice president of Preclinical Development at CANbridge, Beijing. Prior to CANbridge Dr. Hu spent 10 years at Covance Laboratory and held senior scientific positions as Toxicology Senior Study Director, Immunotoxicology Lead Scientist at Covance U.S. and most recently Early Development Scientific Director at Covance Shanghai. Dr. Hu was a Lee Kuan Yew Research Fellow and Principal Investigator at the Department of Microbiology, Faculty of Medicine at National University of Singapore. He received his Medical Degree from West China University of Medical Sciences and subsequently practiced for 3 years in Clinical Immunology at Huaxi University Hospital. He was a Postdoctoral Fellow in immunology and toxicology at the NIH where he successfully cloned and functionally evaluated a recombinant immunotoxin that has been developed and tested in a Phase II clinical trial for skin T cell lymphoma. He co-authored over 50 publications in peer-reviewed international journals and is an inventor on close to 20 U.S., Europe and China issued or pending patents.
Kenneth L. Hastings, Ph.D, DABT, Fellow A.T.S., received his Doctor of Public Health degree from the School of Public Health, University of North Carolina at Chapel Hill, in 1987. Dr. Hastings then served as a US Peace Corps Volunteer in Fiji under the Permanent Secretary for Health. Dr. Hastings served on numerous committees and working groups while at FDA, including lead representative for CDER/FDA on the ICCVAM validation of the murine local lymph node assay and as lead negotiator on ICH S8 (Immunotoxicology Evaluation of New Drugs). Dr. Hastings served as President of the American Board of Toxicology and has numerous publications, included editor of books on use of mini-pigs in biomedical research and international standards for nonclinical safety evaluation of medical products. Dr. Hastings is currently an independent consultant specializing in toxicology studies in drug development.

Marie-Soleil Christin-Piché, Ph.D, is the Scientific Director of the immunology group at Charles River Montreal. She has been with Charles River for over 8 years and currently manages a group of scientists working on small molecules, biotherapeutics and vaccines in several different areas. Her expertise is in the areas of biotherapeutic drug safety and immunotoxicology, and her group assesses the effects of drugs on the immune system and specializes in pre-clinical and clinical development. Dr. Marie-Soleil Piché received her Bsc in microbiology and immunology from McGill University, a Masters of Science in Immunotoxicology from the Armand Frappier Institute, and her PhD in Autoimmunity from the University of Montreal. Dr. Marie-Soleil Piché is an active member of the ILSI/HESI Immunotoxicology Technical Committee.
Jing Ma, Ph.D, director of National Shanghai Center for New Drug Safety Evaluation and Research. From 2003 to 2004, she went to University of Alabama at Birmingham as visiting scholar. She is Executive Council Member and Vice Executive Secretary of Chinese Society of Toxicology, and as the committee member of Toxicology and Drug Evaluation Committee in CSOT, Director of the Toxicology Committee in Chinese Society of Pharmacology, Vice President of Shanghai Pharmaceutical Society, Director of the Toxicology Committee in Shanghai Society of Pharmacology, Council member of Pharmacology Professional Committee in Shanghai Pharmaceutical Society. Dr. Ma serves as a senior GLP inspector of CFDA, and a panel member of CFDA CDE reviewer and EPA reviewer, expert for chemical environmental management in Ministry of Environmental Protection of China. She also served as member of the Editorial Board for "Chinese Journal of Pharmaceuticals", "Chinese Pharmacological Bulletin", "Chinese Adverse Drug Reactions Journal".

 

附件 会议议程和参会回执

 

京公网安备 11010802012717 ICP 13002039

版权所有 中国毒理学会 访问统计

地址: 北京海淀区太平路27 电子邮件:cst@chntox.org

电话:010-66932387 传真:010-68183899 邮编:100850